CD274 and neoplasm: Given that these immunostimulating events can be counteracted by PD-L1 expression in tumor cells, it is not surprising that inhibiting PD-L1 by immunotherapy approaches such as PD1 antibodies (i.e., pembrolizumab) shows favorable results in combination with radiation [168,169].